Quantcast

Latest leukemia Stories

2014-10-17 08:25:55

SUNNYVALE, Calif., Oct. 17, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the European Commission (EC) has granted marketing approval for IMBRUVICA(®) (ibrutinib) throughout the 28 member states of the European Union (EU). IMBRUVICA, a first-in-class, oral, once-daily, non-chemotherapy treatment, now is approved to be marketed in Europe for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with...

2014-10-15 16:30:25

- Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL0191 EAST HANOVER, N.J., Oct. 15, 2014 /PRNewswire/ -- Novartis and the University of Pennsylvania's Perelman School of Medicine (Penn) today announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine (NEJM) evaluating the efficacy and safety of CTL019 in patients...

2014-10-15 16:30:22

University of Pennsylvania and Children's Hospital of Philadelphia Research Team Funded by LLS for More Than 22 Years Report Today in New England Journal of Medicine that 90 Percent of Patients Achieved Complete Remission WHITE PLAINS, N.Y., Oct. 15, 2014 /PRNewswire-USNewswire/ -- Funding from The Leukemia & Lymphoma Society (LLS) over the past 22 years helped advance a study published today in the New England Journal of Medicine showing that 90 percent of children and adults...

2014-10-15 12:32:38

ST. PETERSBURG, Russia, October 15, 2014 /PRNewswire/ -- Russian pharmaceutical companies are actively squeezing out foreign therapeutic manufacturers from the government tenders. The atients' support state program allocates the highest budget for rituximab, a drug used in the treatment of hematological cancers. In 2013, 217 million dollars were appropriated from the federal budget for this drug alone. This year, for the first time, Russian biosimilar drug AcellBia will be...

2014-10-14 12:30:31

NEW BRUNSWICK, N.J., Oct. 14, 2014 /PRNewswire-USNewswire/ -- Actinobac Biomed Inc., has received a $905,040 Small Business Technology Transfer Grant (STTR) Phase II Award from the National Institutes of Health/ National Cancer Institute to continue to develop its drug candidate, Leukothera®, as a potential treatment for B-cell lymphomas. "This NIH grant supports our assertion that Actinobac scientists are working on breakthrough research that can make a tremendous difference for...

2014-10-09 16:27:54

Additional Global Regulatory Filings Reinforce Commitment to Addressing Significant Unmet Needs for Patients With This Aggressive Cancer With Limited Treatment Options THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE(®)) antibody construct, blinatumomab. The BLA is for the...

2014-09-29 12:29:44

Highly distinguished advisory board to strengthen incorporation of Next Generation Sequencing (NGS) into clinical care for patients with blood cancers SEATTLE, Sept. 29, 2014 /PRNewswire/ -- Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing to profile the adaptive immune system, announced today that it has established a Scientific Advisory Board to provide strategic and clinical guidance for the implementation of its clinical...

2014-09-29 08:31:43

Expansion of Collaboration Enables Identification of Optimal Patient Profiles and Combination Strategies for APTO-253 SAN DIEGO, CA AND TORONTO, ON; PORTLAND, OR AND WHITE PLAINS, NY, Sept. 29, 2014 /PRNewswire/ - Aptose Biosciences Inc. (TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, the Knight Cancer Institute at Oregon Health & Science University (OHSU) and The Leukemia &...

2014-09-24 12:29:29

St. Jude Children's Research Hospital study shows that adjusting treatment based on early response to chemotherapy boosts survival of young patients with Philadelphia chromosome-like acute lymphoblastic leukemia MEMPHIS, Tenn., Sept. 24, 2014 /PRNewswire-USNewswire/ -- St. Jude Children's Research Hospital investigators found that adjusting treatment based on early response to chemotherapy made a life-saving difference to young patients with an acute lymphoblastic leukemia (ALL)...

2014-09-24 12:29:26

Collaborative efforts with leading cancer centers to provide clinical test is supported CAMBRIDGE, Mass., Sept. 24, 2014 /PRNewswire/ -- EUTROPICS Inc., a privately held company developing novel diagnostic tests, today announced that it has signed a contract with the National Cancer Institute through the Small Business Initiative Research (NCI-SBIR) program to develop its' Praedicare Dx platform for personalized medicine approaches in Acute Myeloid Leukemia (AML) patient management....


Latest leukemia Reference Libraries

Clinical Leukemia
2012-05-18 15:34:28

Clinical Leukemia is a peer-reviewed medical journal published by CIG Media Group. The journal publishes articles on detection, diagnosis, prevention, and treatment of leukemia. The main emphasis is on recent scientific developments in all areas related to leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance, gene and antisense therapy; pathology, markers, and prognostic indicators, chemoprevention strategies,...

More Articles (1 articles) »
Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related